A combination drug treatment can reduce agitation in patients with probable Alzheimer’s disease and is generally well tolerated, preliminary research published in JAMA has shown.
Click for article
The phase II double blind randomised clinical trial showed that patients who received the combination dextromethorphan hydrobromide and quinidine sulphate had lower occurrence and severity of agitation than patients who received placebo. This combination is approved in the United States and the European Union for treating pseudobulbar affect, a neurological disorder characterised by uncontrollable episodes of crying.
